Outlook Therapeutics, Inc.
Public company- Headquarters
- ISELIN, New Jersey
- Industry
- Biotechnology
- Ticker
- OTLK
- CIK
- 0001649989
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CFOKevin Lundquist | Aug 27, 2026 | Appointed |
| member of the Company’s Board of DirectorsLawrence A. Kenyon | Aug 27, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ANAVEX LIFE SCIENCES CORP.
CEO appointed: Terrie Kellmeyer, Ph.D.
- RECURSION PHARMACEUTICALS, INC.
Chair of the Board appointed: Fred Hassan
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- AMGEN INC
director appointed: David W. Gibbs
- Executive appointment
CFO appointed: Kevin Lundquist
Kevin Lundquist was named Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer of Outlook Therapeutics, Inc., effective September 1, 2026. Kevin Lundquist succeeds Lawrence A. Kenyon. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 27, 2026Role: Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer
- Executive departure
member of the Company’s Board of Directors departs: Lawrence A. Kenyon
Lawrence A. Kenyon, member of the Company’s Board of Directors of Outlook Therapeutics, Inc., departs the role. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 27, 2026Role: member of the Company’s Board of Directors
Last verified Nov 8, 2026